Literature DB >> 33402458

Low DUSP4 Expression Is Associated With Aggressive Phenotypes and Poor Prognosis in Gastric Cancer.

Seung Sam Paik1, Seongsik Bang2, Seungyun Jee2, Hyunsung Kim2, Kiseok Jang2, Hosub Park2, Jae Kyung Myung2, Dongho Choi3, Su-Jin Shin4.   

Abstract

BACKGROUND/AIM: Dual-specificity protein phosphatase 4 (DUSP4) negatively regulates MAPK signaling and is involved in various cellular processes. We herein evaluated the relationship between DUSP4 expression and clinicopathological characteristics in a large series of gastric cancer samples.
MATERIALS AND METHODS: DUSP4 expression was examined by immunohistochemistry in 508 gastric cancer samples. Cases were classified according to the TCGA molecular classification and HER2 amplification. Kaplan-Meier plots were used to predict the relationship between mRNA expression of DUSP4 and survival.
RESULTS: Low expression of DUSP4 was significantly correlated with larger tumor size, higher pT category, positive nodal status, higher stage, lymphovascular invasion, perineural invasion, worse overall survival, and worse recurrence-free survival. No correlation was observed between DUSP4 expression and molecular characteristics. Bioinformatics analysis showed that low mRNA expression was associated with a poor prognosis.
CONCLUSION: Low expression of DUSP4 is associated with aggressive phenotypes of gastric cancer and a poor prognosis. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  DUSP4; Gastric cancer; dual-specificity protein phosphatase 4; prognosis

Mesh:

Substances:

Year:  2021        PMID: 33402458      PMCID: PMC7880801          DOI: 10.21873/invivo.12240

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  27 in total

1.  IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition.

Authors:  Miriam Gaggianesi; Alice Turdo; Aurora Chinnici; Elisa Lipari; Tiziana Apuzzo; Antonina Benfante; Isabella Sperduti; Simone Di Franco; Serena Meraviglia; Elena Lo Presti; Francesco Dieli; Valentina Caputo; Gabriella Militello; Salvatore Vieni; Giorgio Stassi; Matilde Todaro
Journal:  Cancer Res       Date:  2017-04-11       Impact factor: 12.701

2.  MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4.

Authors:  Xiaofeng Xu; Feng Gao; Jianjiang Wang; Lan Tao; Jinsong Ye; Li Ding; Wei Ji; Xing Chen
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

3.  Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.

Authors:  M T Yip-Schneider; A Lin; M S Marshall
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

4.  Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.

Authors:  Michelle L Baglia; Qiuyin Cai; Ying Zheng; Jie Wu; Yinghao Su; Fei Ye; Ping-Ping Bao; Hui Cai; Zhiguo Zhao; Justin Balko; Wei Zheng; Wei Lu; Xiao-Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2014-10-04       Impact factor: 4.872

5.  Clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast.

Authors:  Hyunsung Kim; Se Min Jang; Hyein Ahn; Jongmin Sim; Kijong Yi; Yumin Chung; Hulin Han; Abdul Rehman; Min Sung Chung; Kiseok Jang; Seung Sam Paik
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

6.  Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.

Authors:  Abhijit Mazumdar; Graham M Poage; Jonathan Shepherd; Anna Tsimelzon; Zachary C Hartman; Petra Den Hollander; Jamal Hill; Yun Zhang; Jenny Chang; Susan G Hilsenbeck; Suzanne Fuqua; C Kent Osborne; Gordon B Mills; Powel H Brown
Journal:  Breast Cancer Res Treat       Date:  2016-07-08       Impact factor: 4.872

7.  Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes.

Authors:  Otília Menyhart; Tatsuhiko Kakisaka; Lőrinc Sándor Pongor; Hiroyuki Uetake; Ajay Goel; Balázs Győrffy
Journal:  Cancers (Basel)       Date:  2019-07-14       Impact factor: 6.639

Review 8.  Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.

Authors:  Antonio Pellino; Erika Riello; Floriana Nappo; Stefano Brignola; Sabina Murgioni; Selma Ahcene Djaballah; Sara Lonardi; Vittorina Zagonel; Massimo Rugge; Fotios Loupakis; Matteo Fassan
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

9.  Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients.

Authors:  A Marcell Szász; András Lánczky; Ádám Nagy; Susann Förster; Kim Hark; Jeffrey E Green; Alex Boussioutas; Rita Busuttil; András Szabó; Balázs Győrffy
Journal:  Oncotarget       Date:  2016-08-02

10.  DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.

Authors:  Xing Kang; Minhuan Li; Hao Zhu; Xiaofeng Lu; Ji Miao; Shangce Du; Xuefeng Xia; Wenxian Guan
Journal:  Oncotarget       Date:  2017-10-04
View more
  2 in total

Review 1.  Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.

Authors:  Zahra Zandi; Bahareh Kashani; Zivar Alishahi; Atieh Pourbagheri-Sigaroodi; Fatemeh Esmaeili; Seyed H Ghaffari; Davood Bashash; Majid Momeny
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-04       Impact factor: 4.553

2.  ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis.

Authors:  Lei Wu; Shengnan Sun; Fei Qu; Xiuxiu Liu; Meili Sun; Ying Pan; Yan Zheng; Guohai Su
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.